COMPARATIVE EFFECTIVENESS OF ENTECAVIR VERSUS TENOFOVIR FOR PREVENTING HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B: A COMPREHENSIVE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/rgnxfv10Keywords:
Entecavir, tenofovir, hepatocellular carcinoma (HCC), chronichepatitis B.Abstract
Background: Chronic hepatitis B (CHB), a hepatotropic infection affecting over 250 million people worldwide is associated with a long-term risk of hepatocellular carcinoma (HCC), the most common primary cancer of the liver. HCC incidence is increasing; it is the fifth most common cause of cancer worldwide, and the third leading cause of cancer-related death.
The aim: The aim of this study to show about comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B.
Methods: By the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. This search approach, publications that came out between 2014 and 2024 were taken into account. Several different online reference sources, like Pubmed, SagePub, and Google Scholar were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, , the results of our search get 20 articles, whereas the results of our search on SagePub get 47 articles, on Google Scholar 8810 articles. Records remove before screening are 6028, so we get 2849 articles fos screening. After we screened based on record exclude, we compiled a total of 12 papers. We included five research that met the criteria.
Conclusion: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC).
References
Dave S, Park S, Murad MH, Barnard A, Prokop L, Adams LA, et al. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Hepatology. 2021;73(1):68–78.
Tan DJH, Ng CH, Tay PWL, Syn N, Muthiah MD, Lim WH, et al. Risk of Hepatocellular Carcinoma with Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Metaanalysis. JAMA Netw Open. 2022;5(6):1–15.
Choi WM, Yip TCF, Wong GLH, Kim WR, Yee LJ, Brooks-Rooney C, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data metaanalysis. J Hepatol [Internet]. 2023;78(3):534–42. Available from: https://doi.org/10.1016/j.jhep.2022.12.007 [4] Choi WM, Choi J, Lim YS. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol [Internet].
;19(2):246-258.e9. Available from: https://doi.org/10.1016/j.cgh.2020.05.008
Shahini E, Donghia R, Facciorusso A. The power of prevention: how tenofovir and entecavir are changing the game in hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2023;12(6):936–40.
Huang ZH, Lu GY, Qiu LX, Zhong GH, Huang Y, Yao XM, et al. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. BMC Cancer [Internet]. 2022;22(1):1–12. Available from: https://doi.org/10.1186/s12885-02209413-7
Huang YH, Shen CW, Chen CY, Bair MJ. Comparative effectiveness of tenofovir versus entecavir in patients with hepatitis B virus-related cirrhosis in Taiwan: a retrospective cohort study. Front Pharmacol. 2023;14(December):1–11.
Choi H, Seo GH. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea. J Korean Med Sci [Internet]. 2021;36(14). Available from: https://jkms.org/DOIx.php?id=10.3346/jkms.2021.36.e89
Su F, Berry K, Ioannou GN. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut. 2021;70(2):370–8.
Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of Hepatocellular Carcinoma in Patients Treated with Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study. JAMA Oncol. 2019;5(1):30–6.
Yip TCF, Wong VWS, Chan HLY, Tse YK, Lui GCY, Wong GLH. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China [Internet]. Vol. 158, Gastroenterology. The American Gastroenterological Association; 2020. 215-225.e6 p. Available from: https://doi.org/10.1053/j.gastro.2019.09.025
Lee SW, Choi J, Kim SU, Lim YS. Entecavir versus tenofovir in patients with chronic hepatitis b: Enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol. 2021;27(3):1–10.
Pan LX, Wang YY, Li ZH, Luo JX, Wu KJ, Liu ZX, et al. Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial. Trials [Internet]. 2024;25(1):1–9. Available from: https://doi.org/10.1186/s13063-023-07742-x
Yuan J, Peng Y, Hao FB, Wang YQ, Wang CR, Zhong GC. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis. Aging (Albany NY). 2021;13(5):7147–65.
Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol [Internet]. 2020;5(12):1039–52. Available from: http://dx.doi.org/10.1016/S2468-1253(20)30249-1
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
